

**Product Name** : Camizestrant  
**Cat. No.** : PC-72606  
**CAS No.** : 2222844-89-3  
**Molecular Formula** : C<sub>24</sub>H<sub>28</sub>F<sub>4</sub>N<sub>6</sub>  
**Molecular Weight** : 476.524  
**Target** : Estrogen Receptor/ERR  
**Solubility** : 200 mM in DMSO (95.3 mg/mL)

H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys(1)-Ser-Glu-Tyr-Leu-Asp-Ser-G  
Ala-Gly-Gly-OH.palmitoyl-Glu(1)-OH (acetate salt)

## Biological Activity

AZD9833 (Camizestrant) is an orally bioavailable, highly potent, next-generation selective **estrogen receptor** degrader (SERD) and antagonist with both EC<sub>50</sub> of <1 nM (ER $\alpha$  receptor) in MCF7 cells.

AZD9833 demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ER $\alpha$  in both MCF-7 and CAMA-1 cell lines.

In contrast to AZD9496, AZD9833 does not cause ER agonism in the endometrial carcinoma cell line Ishikawa in vitro and does not cause an increase in the thickness of the endometrium in juvenile rats.

AZD9833 completely suppresses tumor growth in several patient-derived and cell line xenograft models, including models with clinically relevant ESR1 mutations.

## References

Bamberg K, et al. *PLoS One*. 2018 Feb 23;13(2):e0193380.

Granberg KL, et al. *J Med Chem*. 2019 Feb 14;62(3):1385-1406.

Whittaker A, et al. *Clin Transl Sci*. 2020 Mar;13(2):275-283.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com